NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

DBV Technologies S.A (PA: DBV)

 
DBV Technical Analysis
4
As on 9th Jun 2023 DBV STOCK Price closed @ 3.41 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.39 & Strong Buy for SHORT-TERM with Stoploss of 2.71 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

DBVSTOCK Price

Open 3.43 Change Price %
High 3.46 1 Day -0.02 -0.58
Low 3.37 1 Week 0.05 1.49
Close 3.41 1 Month 0.50 17.18
Volume 69455 1 Year 0.35 11.44
52 Week High 5.29 | 52 Week Low 2.20
 
PA France Most Active Stocks
FTI 5.91 -1.66%
VIEDS 0.72 4.35%
ALDRV 0.01 0.00%
AF 1.73 1.76%
CGG 0.69 -2.82%
ALVMG 0.50 0.00%
ACA 10.83 -0.91%
ALJXR 0.01 0.00%
CS 26.52 -2.00%
GLE 23.32 1.92%
 
PA France Top Gainers Stocks
ALAGP 5.50 13.40%
ALSEN 0.32 10.34%
MLPAP 0.55 10.00%
ALMAR 1.15 9.52%
CO 6.03 8.84%
CO 6.03 8.84%
CO 6.03 8.84%
ALGAU 1.92 8.47%
2MX 7.46 8.43%
ATA 0.13 8.33%
 
PA France Top Losers Stocks
AKOM 4.06 -37.05%
AKOM 4.06 -37.05%
FPN 0.02 -33.33%
MLWEL 0.23 -28.12%
ALPHA 0.08 -27.27%
ALPHA 0.08 -27.27%
MLCLP 4.48 -25.95%
ALHYG 0.05 -16.67%
ALLIX 10.80 -13.60%
MLERO 2.52 -12.50%
 
 
DBV
Daily Charts
DBV
Intraday Charts
Whats New @
Bazaartrend
DBV
Free Analysis
 
DBV Important Levels Intraday
RESISTANCE3.58
RESISTANCE3.53
RESISTANCE3.49
RESISTANCE3.46
SUPPORT3.36
SUPPORT3.33
SUPPORT3.29
SUPPORT3.24
 
DBV Forecast May 2024
4th UP Forecast5.01
3rd UP Forecast4.5
2nd UP Forecast4.18
1st UP Forecast3.86
1st DOWN Forecast2.96
2nd DOWN Forecast2.64
3rd DOWN Forecast2.32
4th DOWN Forecast1.81
 
DBV Weekly Forecast
4th UP Forecast3.89
3rd UP Forecast3.74
2nd UP Forecast3.64
1st UP Forecast3.55
1st DOWN Forecast3.27
2nd DOWN Forecast3.18
3rd DOWN Forecast3.08
4th DOWN Forecast2.93
 
DBV Forecast2024
4th UP Forecast9.79
3rd UP Forecast7.74
2nd UP Forecast6.48
1st UP Forecast5.21
1st DOWN Forecast1.61
2nd DOWN Forecast0.34
3rd DOWN Forecast-0.92
4th DOWN Forecast-2.97
 
 
DBV Other Details
Segment EQ
Market Capital 368842336.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
DBV Address
DBV
 
DBV Latest News
 
Your Comments and Response on DBV Technologies S.A
 
DBV Business Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. Address: 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service